The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited a transformative era in fibrosis research. As focus shifts to other fibrotic diseases such as fibrosing IBD, cardiac fibrosis, and kidney fibrosis, the 8th Antifibrotic Drug Development Summit emerged as the definitive forum for innovation.

Uniting key decision-makers over three days, this summit dove into the latest breakthroughs, from discovery and novel targets to preclinical models and early-stage clinical trials, offering unparalleled insights to accelerate antifibrotic therapy development.